Teva-Salbutamol Sterinebs P.F. · DIN 02173360 · 2 mg/mL · Inh Sol- 2.5mL Pk
Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Salbutamol Sterinebs P.F. · DIN 02173360
Manufacturer: Teva Canada Limited; listing date 1997-04-10
Health Canada: Marketed since 2012-07-05 · brand TEVA-SALBUTAMOL STERINEBS P.F. · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG/ML · company Teva canada limited · schedule Prescription
Ministry pays: $0.6750 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02173360)
Source record
DIN 02173360: Teva-Salbutamol Sterinebs P.F.
Raw flags: sec12=Y, sec3=Y
Item: 121200070; group id 233; item number 0413; lccId 00041; manufacturer id TEV
Source form: Inh Sol- 2.5mL Pk; strength: 2mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6871; ministry $0.6750
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02173360
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19058
Interchangeable products
PMS-Salbutamol · DIN 02208237 · $0.6750
Ventolin Nebules P.F. · DIN 02213427 · not recorded
Shortage status: resolved shortage (ended June 20, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02173360
Shortage record checked October 6, 2026